Objective To analyze the short term prognosis of very low birth weight (VLBW) infants. Methods The clinical data of VLBW infants who were hospitalized from December 2013 to December 2014 and followed up to 6 months of corrected age were retrospectively analyzed. Results A total of 230 VLBW infants were enrolled. Thirty infants (13.0%) died during hospitalization, 40 infants (17.4%) were given up the treatment, 60 infants (26.1%) were improved at discharge, and 100 infants (43.4%) were cured at discharge. In the 30 cases of death, causes of death were mainly neonatal respiratory distress syndrome (18 cases), pulmonary hemorrhage (5 cases), and sepsis (3 cases). In the 200 survived infants at discharge, at 6 months of corrected age of follow-up, 13 infants (6.5%) were lost to follow-up, and 54 infants (27.0%) died, among whom 40 infants died because of giving up therapeutic intervention due to economic factor or discharges without permission. At 1, 3, 6 month of follow-up, the length and weight of VLBW infants were gradually approaching normal, and, however, at 6 months of corrected age, the length and weight of VLBW infants were still obviously below the children’s growth standard. The length of VLBW infants was more deeply below the growth standard than the weight. In 109 infants who had fundus ophthalmoscope, 21 cases had retinopathy of prematurity (ROP) I, and 7 cases had ROP II. In 98 infants who had the hearing screening test, 5 cases failed in one ear and 11 cases failed in both ears. In 95 infants who had the head magnetic resonance imaging (MRI) examination, 10 cases had intracranial hemorrhage and 9 cases had premature brain injury. In 49 infants who completed the neonatal behavioral neurological assessment (NBNA) at corrected age of 42 weeks, the scores were all lower than 35. In 36 infants who were assessed by Gesell developmental scale at the 3 months of corrected age, 11 cases had mild developmental delay and 2 cases had moderate developmental delay. In 24 infants who were assessed at the 6 months corrected age, only 2 cases had mild developmental delay. VLBW infants had a rapid progress in social contact, social behavior, and gross motor movement. Conclusions Economic, neonatal respiratory distress syndrome, pulmonary hemorrhage, and sepsis are pivotal factors for the survival and quality of life of VLBW infants. The surviving VLBW infants have catch-up growth and development.

Objective:To evaluate the immunogenicity and immune persistence of purified Vero cells rabies vaccine (PVRV) with Zagreb and Essen regimen.Methods:Prospective study: Patients with first Class II exposure to rabies were recruited from the Dog Injury Cinic of Guangxi Center for Disease Control and Prevention (Guangxi CDC) and randomly divided into the Zagreb (2-1-1) and Essen (1-1-1-1-1) regimen group. All patients were inoculated with the vaccines from the same manufacturer and batch, and 3 ml serum was collected at the 45th day and in 1-year, 2-year and 3-year after immunization. Rapid fluorescent inhibition test (RFFIT) was used to detect rabies virus neutralizing antibody (RVNA). The attenuation of RVNA positive rate and geometric mean titer (GMT) with time was analyzed. Retrospective study: The informed consents for rabies vaccine in the Dog Injury Clinic of Guangxi CDC were checked out. The patients who were injected with PVRV (same manufacturer but unlimited batch) but without passive immune agents for the first time within 3 years were selected and divided into 1-year, 2-year and 3-year group. Each group was further divided into Zagreb and Essen regimen group. The serum (3 ml) was collected at 1 year, 2 years and 3 years after immunization and detected the RVNA by RFFIT.Results:Prospective study: The RVNA positive rates on the 45th day and in 1-year, 2-year and 3-year after immunizationin in the Zagreb and Essen regimen group were 100%, 95%, 85%, 80% and 98.25%, 89.47%, 89.47%, 85.96%, respectively. There was no statistically significant difference in the RVNA positive rates at the same time point between the two regimen groups ( P>0.05). The RVNA GMT on the 45th day and in 1-year, 2-year, and 3-year in the Zagreb and Essen regimen group were 11.32 IU/ml, 1.69 IU/ml, 1.30 IU/ml, 1.30 IU/m and 13.18 IU/ml, 2.13 IU/ml, 1.87 IU/ml, 1.84 IU/m, respectively. There was no significant difference in the RVNA GMT levels at the same time point between the two regimen groups ( F=1.971, P=0.164). The RVNA GMT levels in the two regimen groups had the same trend of attenuation over time (time*group F=0.702, P=0.435). Retrospective study: The RVNA positive rates in 1-year, 2-year and 3-year after immunization in the Zagreb and Essen regimen group were 100%, 95%, 91.43%和94.73%, 86.21%, 87.5%, respectively. There was no statistically significant difference in the RVNA positive rates at the same time point between the two regimen groups ( P>0.05). The RVNA GMT in 1-year, 2-year, and 3-year groups after immunization in the Zagreb and Essen regimen group were 2.65 IU/ml, 2.03 IU/ml, 1.57 IU/ml和3.2 IU/ml, 2.58 IU/ml, 2.45 IU/ml, respectively. There was no significant difference in the RVNA GMT levels at the same time point between the two regimen groups ( P>0.05). Conclusions:The PVRV showed the same excellent immunogenicity and immune persistence after the vaccination with the Zagreb and Essen regimens.